SEARCH

SEARCH BY CITATION

References

  • 1
    Call KM, Glaser T, Ito CY et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms’ tumor locus. Cell 1990; 60: 50920.
  • 2
    Gashler AL, Bonthron DT, Madden SL, Rauscher FJ 3rd, Colins T, Sukhatme VP. Human platelet-derived growth factor A chain is transcriptionally repressed by the Wilms tumor suppressor WT1. Proc Natl Acad Sci USA 1992; 89: 10 984–8.
  • 3
    Harrington MA, Konicek B, Song A, Xia XL, Fredericks WJ, Rauscher FJ 3rd. Inhibition of colony-stimulating factor-1 promoter activity by the product of the Wilms’ tumor locus. J Biol Chem 1993; 268: 21 271–5.
  • 4
    Drummond IA, Madden SL, Rohwer-Nutter P, Bell GI, Sukhatme VP, Rauscher FJ 3rd. Repression of the insulin-like growth factor II gene by the Wilms tumor suppressor WT1. Science 1992; 257: 6748.
  • 5
    Werner H, Re GG, Drummond IA et al. Increased Expression of the insulin-like growth factor I receptor gene, IGF1R, in Wilms tumor is correlated with modulation of IGF1R promoter activity by the WT1 Wilms tumor gene product. Proc Natl Acad Sci USA 1993; 90: 582832.
  • 6
    Goodyer P, Dehbi M, Torban E, Bruening W, Pelletier J. Repression of the retinoic acid receptor-α gene by the Wilms’ tumor suppressor gene product, wt1. Oncogene 1995; 10: 11259.
  • 7
    Larsson SH, Charlieu JP, Miyagawa K et al. Subnuclear localization of WT1 in splicing or transcription factor domains is regulated by alternative splicing. Cell 1995; 81: 391401.
  • 8
    Davies RC, Calvio C, Bratt E, Larsson SH, Lamond AI, Hastie ND. WT1 interacts with the splicing factor U2AF65 in an isoform-dependent manner and can be incorporated into spliceosomes. Genes Dev 1998; 12: 321725.
  • 9
    Niksic M, Slight J, Sanford JR, Caceres JF, Hastie ND. The Wilms’ tumour protein (WT1) shuttles between nucleus and cytoplasm and is present in functional polysomes. Hum Mol Genet 2004; 13: 46371.
  • 10
    Inoue K, Sugiyama H, Ogawa H et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994; 84: 30719.
  • 11
    Oji Y, Miyoshi S, Maeda H et al. Overexpression of the Wilms’ tumor gene WT1 in de novo lung cancers. Int J Cancer 2002; 100: 297303.
  • 12
    Oji Y, Yamamoto H, Nomura M et al. Overexpression of the Wilms’ tumor gene WT1 in colorectal adenocarcinoma. Cancer Sci 2003; 94: 71217.
  • 13
    Oji Y, Yano M, Nakano Y et al. Overexpression of the Wilms’ tumor gene WT1 in esophageal cancer. Anticancer Res 2004; 24: 31038.
  • 14
    Loeb DM, Evron E, Patel CB et al. Wilms’ tumor suppressor gene (WT1) is expressed in primary breast tumors despite tumor-specific promoter methylation. Cancer Res 2001; 61: 9215.
  • 15
    Miyoshi Y, Ando A, Egawa C et al. High expression of Wilms’ tumor suppressor gene predicts poor prognosis in breast cancer patients. Clin Cancer Res 2002; 8: 116771.
  • 16
    Oji Y, Miyoshi Y, Koga S et al. Overexpression of the Wilms’ tumor gene WT1 in primary thyroid cancer. Cancer Sci 2003; 94: 60611.
  • 17
    Oji Y, Nakamori S, Fujikawa M et al. Overexpression of the Wilms’ tumor gene WT1 in pancreatic ductal adenocarcinoma. Cancer Sci 2004; 95: 5837.
  • 18
    Oji Y, Inohara H, Nakazawa M et al. Overexpression of the Wilms’ tumor gene WT1 in head and neck squamous cell carcinoma. Cancer Sci 2003; 94: 5239.
  • 19
    Ueda T, Oji Y, Naka N et al. Overexpression of the Wilms’ tumor gene WT1 in human bone and soft-tissue sarcomas. Cancer Sci 2003; 94: 2716.
  • 20
    Oji Y, Suzuki T, Nakano Y et al. Overexpression of the Wilms’ tumor gene WT1 in primary astrocytic tumors. Cancer Sci 2004; 95: 8227.
  • 21
    Sugiyama H. Cancer immunotherapy targeting WT1 protein. Int J Hematol 2002; 76: 12732.
  • 22
    Harada Y, Nonomura N, Nishimura K et al. WT1 gene expression in human testicular germ-cell tumors. Mol Urol 1999; 3: 35764.
  • 23
    Osaka M, Koami K, Sugiyama T. WT1 contributes to leukemogenesis: expression patterns in 7,12-dimethylbenz[a]anthracene (DMBA)-induced leukemia. Int J Cancer 1997; 72: 6969.
  • 24
    Yamagami T, Sugiyama H, Inoue K et al. Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis. Blood 1996; 87: 287884.
  • 25
    Algar EM, Khromykh T, Smith SI, Blackburn DM, Bryson GJ, Smith PJ. A WT1 antisense oligonucleotide inhibits proliferation and induces apoptosis in myeloid leukaemia cell lines. Oncogene 1996; 12: 100514.
  • 26
    Oji Y, Ogawa H, Tamaki H et al. Expression of the Wilms’ tumor gene WT1 in solid tumors and its involvement in tumor cell growth. Jpn J Cancer Res 1999; 90: 194204.
  • 27
    Inoue K, Tamaki H, Ogawa H et al. Wilms’ tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells. Blood 1998; 91: 296976.
  • 28
    Tsuboi A, Oka Y, Ogawa H et al. Constitutive expression of the Wilms’ tumor gene WT1 inhibits the differentiation of myeloid progenitor cells but promotes their proliferation in response to granulocyte-colony stimulating factor (G-CSF). Leuk Res 1999; 23: 499505.
  • 29
    Siehl JM, Reinwald M, Heufelder K, Menssen HD, Keilholz U, Thiel E. Expression of Wilms’ tumor gene 1 at different stages of acute myeloid leukemia and analysis of its major splice variants. Ann Hematol 2000; 83: 74550.
  • 30
    Salazar R, Bell SE, Davis GE. Coordinate induction of the actin cytoskeletal regulatory proteins gelsolin, vasodilator-stimulated phosphoprotein, and profilin during capillary morphogenesis in vitro. Exp Cell Res 1999; 249: 2232.
  • 31
    Yu DH, Qu CK, Henegariu O, Lu X, Feng GS. Protein-tyrosine phosphatase Shp-2 regulates cell spreading, migration, and focal adhesion. J Biol Chem 1998; 273: 21 125–31.
  • 32
    Grille SJ, Bellacosa A, Upson J et al. The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. Cancer Res 2003; 63: 21728.
  • 33
    Stahle M, Veit C, Bachfischer U et al. Mechanisms in LPA-induced tumor cell migration: critical role of phosphorylated ERK. J Cell Sci 2003; 116: 383546.
  • 34
    Yoshioka K, Foletta V, Bernard O, Itoh K. A role for LIM kinase in cancer invasion. Proc Natl Acad Sci USA 2003; 100: 724752.
  • 35
    Otey CA, Carpen O. α-Actinin revisited: a fresh look at an old player. Cell Motil Cytoskeleton 2004; 58: 10411.
  • 36
    Southwick FS. Gelsolin and ADF/cofilin enhance the actin dynamics of motile cells. Proc Natl Acad Sci USA 2000; 97: 69368.
  • 37
    Rauscher FJ 3rd, Morris JF, Tournay OE, Cook DM, Curran T. Binding of the Wilms’ tumor locus zinc finger protein to the EGR-1 consensus sequence. Science 1990; 250: 125962.
  • 38
    Hastie ND. Life, sex, and WT1 isoforms − three amino acids can make all the difference. Cell 2001; 106: 3914.
  • 39
    Rupprecht HD, Drummond IA, Madden SL, Rauscher FJ 3rd, Sukhatme VP. The Wilms’ tumor suppressor gene WT1 is negatively autoregulated. J Biol Chem 1994; 269: 6198206.
  • 40
    Hubinger G, Schmid M, Linortner S, Manegold A, Bergmann L, Maurer U. Ribozyme-mediated cleavage of wt1 transcripts suppresses growth of leukemia cells. Exp Hematol 2001; 10: 122635.
  • 41
    Li H, Oka Y, Tsuboi A et al. The lck promoter-driven expression of the Wilms tumor gene WT1 blocks intrathymic differentiation of T-lineage cells. Int J Hematol 2003; 77: 46370.